Sun Pharmaceutical industries has signed a definitive agreement to acquire 100% of U.S.-based Concert Pharma at $8 per share, i.e., $576 million to access the company’s experimental drug for treating patchy baldness. As per the agreement, Concert shareholders will also get non-tradeable contingent value right worth $3.5 per share i.e $252million. The acquisition gives Sun […]
